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Glycoproteins secreted into plasma from T cells infected with human immunodeficiency virus (HIV) latent infection
may provide insight into understanding the host response to HIV infection in vivo. Glycoproteomics, which evaluates
the level of the glycoproteome, remains a novel approach to study this host response to HIV. In order to identify
human glycoproteins secreted from T cells with latent HIV infection, the medium from cultured HIV replication-
competent T cells was compared with the medium from cultured parental A3.01 cells via solid phase extraction of
glycopeptides (SPEG) and high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Using
these methods, 59 human glycoproteins were identified as having significantly different abundance levels between the
media from these two cell lines. The relevance of these 59 proteins to HIV infection in vivo was assessed in plasma from
HIV+ and HIV- subjects. Comparison between T cell and plasma revealed that six glycoproteins (galectin-3-binding
protein, L-selectin, neogenin, adenosine deaminase CECR1, ICOS ligand and phospholipid transfer protein) were
significantly elevated in the HIV+ T cells and plasma studies. These findings suggest that the response of T cells harboring
latent HIV infection contributed, in part, to the glycoprotein changes in HIV+ plasma. These proteins, once validated,
could provide insight into host-HIV interaction.
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In 2011, there were approximately 34 million individuals
living with HIV [1]. In the same year, it is estimated that
there were approximately 2.5 million new infections and
1.7 million AIDS related deaths [1]. Although tremen-
dous efforts have been devoted to prevent HIV transmis-
sion, to date, no effective HIV vaccine is available [2].
Instead, highly active antiretroviral therapy (HAART) is
routinely used to treat patients infected with HIV and it
has been shown to be effective in the prevention of HIV
transmission [3]. HAART has greatly improved the life-
span and quality of life of the HIV infected population
[4]. However, HIV related illnesses such as neurodegen-
erative diseases, cancers, and bacterial infections have
emerged as important issues in HIV+ patients [5-8]. To
identify proteins in a complex sample for the (early)* Correspondence: hzhang32@jhmi.edu
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unless otherwise stated.detection, diagnosis, prognosis, treatment prediction and
the elucidation of the pathogenesis of these diseases,
proteomic studies have demonstrated their applicability
in a high throughput fashion [9-11]. However, the urgent
need for the identification of biomarkers of HIV and its
related diseases remains unmet [8].
HIV is a lentivirus which belongs to the retrovirus
family [12]. It primarily infects immune cells containing
CD4 receptors, such as helper T cells, dendritic cells
(DC) and macrophages, and establishes latent infection
in these cells [13]. An inevitable step in the viral replica-
tion cycle is the integration of viral DNA into the T cell
genome prior to either latent infection or active produc-
tion of virions [14]. The infection of the immune cells,
which reside in the blood and draining lymph tissues, re-
sults in the atypical secretion and shedding of disease-
related proteins into the peripheral blood [15]. Thus, the
blood of patients infected with HIV is considered to be an
excellent source to identify proteins that are associatedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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that aim to discover new biomarkers of HIV and its re-
lated diseases have identified protein abundance changes
in plasma and serum [9,10,16-19].
Glycoproteomics, a sub-proteomic approach that spe-
cifically investigates the levels of glycoproteins in a com-
plex sample, has been widely applied for cancer
biomarker discovery [20-22]. This approach is promising
because glycoproteins are ubiquitous in extracellular se-
cretion, are known to be dysregulated in cancerous cells,
and are likely to enter the bloodstream, making them at-
tractive candidates for cancer biomarkers [23]. The sig-
nificance of glycoproteins as biomarkers has shown
great promise in that most of the U.S. Food and Drug
Administration (FDA) approved cancer biomarkers are
glycoproteins. These biomarkers include prostate-specific
antigen (PSA) for prostate cancer, CA125 for ovarian can-
cer, and CA15-3 for breast cancer [24,25]. In HIV infec-
tion, the host systemic reaction to infection of immune
cells, inflammation, chronic activation, repeated evasion-
recognition and reconstitution of immune system likely
triggers the secretion or shedding of a large number of
glycoproteins into the bloodstream [26,27]. It has been
observed that the global and HIV-specific antibody-
glycosylation profile is altered during HIV infection [28].
It is possible that the aberrant presence of glycoproteins
other than antibodies may be specifically associated with
HIV infection given the unique immune cell tropism of
the virus [13]. However, the change in glycoproteins
caused by HIV infection has not been determined in pre-
vious studies and remains unclear.
In the blood, N-linked glycosylated proteins are par-
ticularly interesting because N-linked glycosylation is a
designated signal for the extracellular secretion of pro-
teins [15,22]. To study the N-linked glycoproteins in a
high throughput manner, we previously developed a
method for the hydrazide chemistry-based solid phase
capture of glycopeptides and coupled it with the use of
PNGase F for the specific release of ‘formerly’ N-
glycosylated peptides (only the peptides originally attached
to glycans) [29-31]. The isolated formerly N-glycosylated
peptides are analyzed by LC separation followed by tan-
dem mass spectrometry (MS/MS), which allows the high
throughput identification and quantification of a large
number of glycoproteins [32-34]. This feature of the tech-
nique provides a unique opportunity to detect protein
changes in plasma-derived immune cells [35,36].
In this study, LC-MS/MS based quantitative glycopro-
teomics was used to examine the altered levels of glyco-
proteins associated with HIV latent infection in T cells
(ACH-2 cell lines) and plasma from HIV+ patients
[29,30]. The advantage of label-free LC-MS-MS/MS
based quantitative glycoproteomics is the ability to com-
pare an unlimited number of samples with a deepercoverage of identification compared to strategies that in-
corporate stable isotope labeling [37,38]. The current
study started with the identification of dysregulated gly-
coproteins from the media of T cell lines with HIV latent
infection to determine putative glycoprotein candidates,
followed by the use of HIV+ plasma to identify the
glycoprotein changes that could be influenced by the ab-
errant secretion of glycoproteins from the T cells harbor-
ing HIV DNA in their genomes. To our knowledge, this
is the first study to identify glycoproteins that are poten-
tially associated with HIV infection in plasma by high




The bicinchoninic acid (BCA) protein assay kit was pur-
chased from Pierce (Rockford, IL); hydrazide support
and sodium periodate were purchased from Bio-Rad
(Hercules, CA); sequencing-grade trypsin was purchased
from Promega (Madison, WI); PNGase F was purchased
from New England Biolabs (Ipswich, MA); Sep-Pak C18
1 cc Vac Cartridges were purchased from Waters (Milford,
MA); and acetonitrile (ACN), trifluoroacetic acid (TFA),
formic acid, urea, tris(2-carboxyethyl)phosphine (TCEP),
iodoacetamide, phorbol 12-myristate 13-acetate (PMA),
5 M NaCl, sodium dodecyl sulfate (SDS), 10× phosphate
buffered saline buffer (PBS) pH 7.4 and 1 M Tris–HCl
pH 8.0 buffer were purchased from Sigma-Aldrich (St.
Louis, MO).
Patient samples
Plasma was tested for HIV antibody and HIV RNA viral
loads were determined if the plasma tested positive for
HIV. The plasma was aliquoted and immediately stored
at −80°C until use (Table 1). Prior to the study, samples
were de-identified. The Johns Hopkins Medicine Institu-
tional Review Board (IRB) approved the use of the
samples.
Cell culture
The HIV-1 latently infected T cell line ACH-2 and its
parental cell line A3.01 were obtained from Dr. Thomas
Folks through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH [39-41]. The
ACH-2 cell line is a sub-clone of the human A3.01 T cell
line derived from acute infection with the LAV strain of
HIV-1. The HIV DNA is integrated into the genome of
the T cell line. Low levels of supernatant RT and p24
antigen are constitutively produced in ACH-2 cells.
HIV-1 replication can be induced with phorbol 12-
myristate 13-acetate (PMA) or IL-2 to produce high
levels of infectious HIV-1. Thus, the cell line is HIV rep-
lication competent. However, we did not stimulate the
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cells were cultured in RPMI 1640 supplemented with
2 mm L-glutamine (Gibco Laboratories, Grand Island,
NY), 100 U/ml penicillin, 100 g/ml streptomycin (Invi-
trogen, Carlsbad, CA) and 10% (v/v) heat-inactivated
fetal calf serum (FCS, Hyclone Laboratories, Logan, UT).
In this study, cells were pelleted and washed in serum
free medium 5 times and resuspended in serum free
medium. After 48 hours of incubation at 37°C in 5%
CO2, the cells were pelleted by low speed centrifugation
and the medium was harvested, filtered through a
0.22 μm filter unit and concentrated using a 3 kDa cut-
off centrifugal filter unit (Millipore, Bedford, MA). The
concentrated medium was diluted in 800 μl of 8 M urea
in 0.2 M Tris–HCl with 0.1% (w/v) SDS solution
(pH 8.0). Protein concentration was determined by BCA
assay.
N-linked glycopeptide isolation
Cell culture media (1 mg protein) and plasma (20 μl
containing approximately 1.6 mg protein) were added to
8 M urea in 0.2 M Tris–HCl with 0.1% (w/v) SDS solu-
tion (pH 8.0). Proteins were reduced with 10 mM TCEP
in Tris–HCl pH 8.0 at 37°C for 1 hour. Proteins were
alkylated with 10 mM iodoacetamide and incubated at
room temperature (RT) in the dark with shaking for
30 min. Samples were diluted into 6 ml 0.2 M Tris–HCl
pH 8.0 to decrease the urea concentration to less than
2 M and to decrease the protein concentration. Trypsin
(0.5 μg/μl, enzyme/protein ratio of 1/40 w/w) was added
to digest the proteins at 30°C overnight. After digestion,
5 μg of sample was resolved on a tricine gel and silver
staining was used to visualize the digestion products.
The disappearance of high molecular bands and the ap-
pearance of a smear of bands with a molecular weightless than 10 kDa indicated the completion of digestion.
The peptides were de-salted using a C18 cartridge ac-
cording to the manufacturer’s instructions and then the
peptides were oxidized by incubation with 10 mM so-
dium periodate in 80% ACN (v/v) 0.1% TFA (v/v) for 1
hour at RT in the dark. The oxidized peptides were puri-
fied by C18 cartridge, eluted in 80% ACN (v/v) 0.1%
TFA (v/v) and mixed with 50 μl of (50% slurry) hydra-
zide support prewashed with 1 ml deionized water. The
mixture was incubated with gentle shaking at RT over-
night for the coupling reaction. The hydrazide support
was washed three times with 800 μl of 1.5 M NaCl
followed by three times with 800 μl of water to remove
non-coupled peptides. The support was finally washed
twice with 200 μl of 1× G7 buffer and incubated with
3 μl of PNGase F in 50 μl of 1× G7 buffer at 37°C to
specifically release formerly N-glycosylated peptides
which were purified by a C18 cartridge. Then, the pep-
tides were dried in a speed-vac and re-suspended in
40 μl of 0.1% formic acid prior to MS analysis. For
pooled glycopeptides, an equal volume (1 μl) of the
formerly N-glycosylated peptides from each sample was
pooled into either the HIV infected or uninfected pools.
LC-MS/MS analysis
The formerly N-glycosylated peptides (1.5 μg) were sep-
arated using a Dionex Ultimate 3000 RELC nano system
(Thermo Scientific) with a 75 μm × 15 cm Acclaim Pep-
Map100 analytical column (Thermo Scientific) protected
by a 2 cm guard column (Thermo Scientific). The mo-
bile phase flow rate was 300 nl/min with 0.1% formic
acid in water (A) and 0.1% formic acid/95% acetonitrile
(B). The gradient profile was set as follows: 4-35% B for
70 min, 35-95% B for 5 min, 95% B for 10 min and
equilibration at 4% B for 15 min. MS analysis was per-
formed using an Orbitrap Velos Pro mass spectrometer
(Thermo Scientific). The spray voltage was set at 2.2 kV.
Orbitrap MS1 spectra (AGC 1×106) were acquired from
400–1800 m/z at 60 K resolution followed by data-
dependent HCD MS/MS (7,500 resolution, collision
energy 45%, activation time 0.1 ms) of the ten most
abundant ions using an isolation width of 2.0 Da. Charge
state screening was enabled to reject unassigned and sin-
gly charged ions. A dynamic exclusion time of 35 sec
was used to discriminate against previously selected
ions.
Protein identification and label-free quantitation
The quality of the Raw files from the LTQ-Orbitrap
Velos Pro was evaluated by the Trans-Proteomic Pipe-
line (TPP) and searched against a human protein data-
base (the International Protein Index human protein
database, version 3.87). The precursor mass tolerance
was 20 ppm and the MS/MS tolerance was 0.06 Da. The
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follows: oxidized methionine (addition of 15.995 Da to
Met), PNGase F-catalyzed conversion of Asn to Asp
(addition of 0.984 Da to Asn) and Cys modification
(addition of 57.021 to Cys). A maximum of two missed
tryptic cleavage sites were used. The assigned peptides
were evaluated by INTERACT and PeptideProphet with
a minimum probability score of 0.7 [42-44]. Label-free
quantitation was performed using MaxQuant ver. 1.3.0.5
and searched against the same human protein IPI data-
base ver. 3.87 containing a total of 91,464 entries [38].
The default parameters with a 1% false discovery rate
(FDR) were used except for the following: enzyme: tryp-
sin; variable modifications: oxidation (M) and deamida-
tion (NQ); and filter labeled amino acid unselected. The
output peptide.txt file containing the identified peptide
sequences and corresponding MS peak intensities were
used for the quantitation.
Data analysis
The output data from MaxQuant were converted to
Microsoft Excel files. First, peptides that were considered
contaminants, peptides that were identified in the re-
verse database search and peptides lacking N deamin-
ation were deleted. Second, peptides without an NXS/T
(where X is any amino acid except proline) motif were
deleted. The intensities of the remaining glycopeptides
were normalized by dividing the total intensity of the
identified glycopeptides in each LC-MS/MS run. The
mean intensity of all the glycopeptides from a glycopro-
tein that had intensities greater than zero was used for
inter-sample protein comparison. Using pooled samples,
a cut-off ratio of 2-fold was used while a Student’s t-test
with a p-value ≤ 0.05 was used to analyze the individual
samples.
Results
Quantitative secretion of glycoproteins from T cells with
HIV latent infection
To address whether HIV latent infection was associated
with aberrant secretion of glycoproteins from T cells,
serum-free culture media of HIV-1 latently infected T-
lymphocyte ACH-2 cells and the parental cell line A3.01
cells were studied through the use of label free glycopro-
teomics. To evaluate the viral production of these two
cultured cell lines, Western blotting-based immunoreac-
tivity of gp120 and gp41 in ACH-2 cells stimulated by
PMA was observed, but no immunoreactivity was de-
tected in A3.01 cells was evident, demonstrating the sta-
tus of latent infection in ACH-2 cells (Additional file 1:
Figure S1). Serum-free medium of T cells was collected
and processed using a SPEG-based method to isolate
formerly N-glycosylated peptides as described in the
Methods section. Subsequently, the reconstituted formerlyglycosylated peptides from each sample were analyzed by
three LC-MS/MS technical replicates. The quality of the
reproducible LC-MS/MS data was inspected using Pep3D
images generated from Trans Proteomic Pipeline (TPP) to
evaluate retention time consistency and MS2 coverage
(Additional file 2: Figure S2). TPP identified 829 unique
glycopeptides from 411 unique glycoproteins with N dea-
midation within the consensus N-linked glycosylation
motif (NXS/T, where X is any amino acid except proline).
The quality of the data that were evaluated by TPP was
adequate for downstream label-free comparison. Accord-
ingly, MaxQuant was used to calculate the peak inten-
sities, resulting in the identification of 671 glycopeptides
from 375 glycoproteins. After normalization, 326 proteins
could be quantitatively compared between the samples
based on their fold-change and p-value (Figure 1). Using
criteria of a fold-change of 3 and a p-value < 0.05, 59 gly-
coproteins were identified as being significantly differen-
tially expressed (Figure 1B & Table 2).
Elevated plasma glycoprotein might be influenced by HIV
latently infected T cells
To determine whether proteins secreted by HIV latently
infected T cells could be detected in HIV+ plasma, 20
plasma samples from 10 HIV+ and 10 HIV- patients
were evaluated. Although the time since HIV infection
was not known, it was possible to assume that all the
HIV+ samples were not recently infected according to
the clinical observation in the HPTN lab. In theory,
these plasma samples could harbor proteins secreted
from T cells with HIV latent infection. A schematic flow
chart of the approach used to study the changes in
glycoprotein relative abundance is shown in Figure 2.
The 20 plasma samples were processed individually
using SPEG-glycoproteomics and pooled as described in
the Methods section. The pooled samples were used to
screen the glycoproteins between these two groups.
Label-free quantification was used to analyze data from
4 consecutive LC-MS/MS runs for the HIV+ pool and 3
LC-MS/MS runs for the HIV- pool. The quality of the
LC-MS/MS data was again evaluated using Pep3D im-
ages (Additional file 3: Figure S3). Eight hundred fifty
unique glycopeptides from 221 unique glycoproteins
were identified by TPP (data not shown). MaxQuant
analysis identified 399 unique glycopeptides from 183
glycoproteins (data not shown). Of these proteins, 103
glycoproteins were quantitatively compared between the
HIV+ and HIV- groups using a cut-off ratio of 1.3-fold
(data not shown). To determine whether these proteins
were quantitatively different in individuals from each
group, an equal volume (1 μl per LC-MS/MS injection)
of the 20 individual plasma samples was analyzed by
LC-MS/MS with 3 technical replicates for each plasma
sample followed again by TPP quality evaluation and
Figure 1 Plots of the 326 proteins for label-free quantitative comparison between ACH-2 and A3.01 cell media. A) Log2 fold-change plot
of the proteins after normalization. B) Volcano plot of the proteins. Proteins with greater than a 3-fold change and p-value < 0.05 are colored in
red and green. Green squares indicate proteins that were also increased in the HIV+ plasma sample.
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glycoproteins were identified). This step semi-verified
and reduced the total number of differentially expressed
proteins from 103 to 38 using a p-value < 0.05 and a cut-
off ratio of 1.5-fold (Table 3). A comparison between the
differential 38 proteins in the plasma and the 59 proteins
detected in the T cell study revealed that four proteins
(galecin-3-binding protein, L-selectin, neogenin and ad-
enosine deaminase CECR1) were identified in both ana-
lyses as having a greater than 3-fold increased relative
abundance in the medium of ACH-2 cells and a 2-fold
increased relative abundance in HIV+ plasma (Table 3).
Noticeably, compared to A3.01 cells, galectin-3-binding
protein demonstrated the most significant upregulation
which was more than 45-fold increased compared to the
level that was detected in the medium of ACH-2 cells(Table 3). In addition, when the 38 proteins in plasma
were searched against the 326 proteins observed in the
T cell medium study, two proteins, phospholipid transfer
protein and ICOS ligand, were found to be increased by
5.1- and 2.6-fold, respectively, although the former had a
p-value slightly greater than 0.05 in the T cell study
(Table 3). The elevated levels of these six proteins in the
medium of ACH-2 cells and HIV+ plasma suggested that
their up-regulation in the HIV+ plasma might be par-
tially due to HIV latently infected T cells.
Discussion
The identification of protein changes in the plasma of
patients infected with HIV could lead to the identifica-
tion of biomarkers that have roles in pathogenesis and
that have clinical applications. However, as an important
Table 2 Differentially expressed proteins in the media of ACH-2 and A3.01 cells
IPI ID Protein name Unique peptide # Fold change p-value
IPI00023673 Galectin-3-binding proteins 6 44.6 4.E-03
IPI00437751 Angiotensin-converting enzyme 2 31.5 2.E-02
IPI00059476 Dipeptidase 1 3 23.3 3.E-02
IPI00010348 Deoxyribonuclease-2-alpha 1 23.1 5.E-03
IPI00171411 Golgi membrane protein 1 2 19.0 2.E-02
IPI00031802 Tumor necrosis factor ligand superfamily member 13B 1 17.8 6.E-03
IPI00472013 HLA class I histocompatibility antigen, A-33 alpha chain 1 12.4 2.E-04
IPI01013306 Highly similar to Homo sapiens L1 cell adhesion molecule 1 11.5 2.E-02
IPI00029419 Hereditary hemochromatosis protein 1 11.1 8.E-05
IPI00745313 Adipocyte enhancer-binding protein 1 2 10.0 5.E-02
IPI00784119 V-type proton ATPase subunit S1 1 9.1 3.E-04
IPI00797223 Serine protease 57 1 8.9 2.E-02
IPI00294834 Aspartyl/asparaginyl beta-hydroxylase 1 8.8 9.E-03
IPI00152540 CD109 antigen 7 8.7 8.E-03
IPI00299083 Junctional adhesion molecule B 1 8.2 2.E-02
IPI00298237 Tripeptidyl-peptidase 1 1 6.8 8.E-03
IPI00787853 Inositol monophosphatase 3 1 6.7 5.E-02
IPI00328113 Fibrillin-1 1 6.5 5.E-04
IPI00175654 Allergin-1 1 5.8 4.E-03
IPI00013744 Integrin alpha-2 2 5.5 2.E-02
IPI00217882 Sortilin 3 5.1 1.E-02
IPI00641181 MARCKS-related protein 1 1 4.9 8.E-03
IPI00176427 Cell adhesion molecule 4 1 4.7 4.E-03
IPI00789911 Lymphocyte antigen 75 9 4.5 1.E-04
IPI00151990 Thioredoxin domain-containing protein 15 1 4.5 1.E-02
IPI00553185 T-complex protein 1 subunit gamma 1 4.5 4.E-02
IPI00374563 Agrin 1 4.2 2.E-02
IPI00163187 Fascin 1 4.2 3.E-02
IPI00009923 Prolyl 4-hydroxylase subunit alpha-1 1 4.1 8.E-03
IPI00031801 DNA-binding protein A 1 4.0 5.E-03
IPI00290085 Cadherin-2 1 3.9 3.E-03
IPI00004084 Cyclic AMP-dependent transcription factor ATF-6 beta 1 3.9 2.E-02
IPI00022608 Sortilin-related receptor 7 3.9 3.E-03
IPI00001793 Beta-1,3-N-acetylglucosaminyltransferase radical fringe 1 3.8 4.E-02
IPI00301459 Group XV phospholipase A2 1 3.8 3.E-03
IPI00303071 Adenosine deaminase CECR1 2 3.8 3.E-02
IPI00983078 Transmembrane 9 superfamily member 1 1 3.5 1.E-02
IPI00980045 CD59 glycoprotein 1 3.4 1.E-02
IPI00020201 CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase 3 3.4 3.E-02
IPI00021794 Lysosomal protective protein 1 3.4 2.E-03
IPI00009629 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 3 3.4 4.E-03
IPI00797738 Cytochrome c oxidase subunit 6B1 1 3.4 3.E-02
IPI00000070 Low-density lipoprotein receptor 1 3.3 4.E-02
IPI00556494 Mediator of RNA polymerase II transcription subunit 4 1 3.3 3.E-03
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IPI00023814 Neogenin 2 3.2 1.E-02
IPI00218795 L-selectin 2 3.2 3.E-02
IPI00893133 MHC class I antigen 1 3.1 2.E-02
IPI00031821 Integral membrane protein 2B 1 3.0 5.E-03
IPI00465261 Endoplasmic reticulum aminopeptidase 2 1 3.0 9.E-03
IPI00168728 FLJ00385 protein 1 -3.2 3.E-02
IPI00299594 Neuropilin-1 1 -3.3 3.E-03
IPI00015476 Neutral amino acid transporter A 1 -3.4 2.E-02
IPI00029739 Complement factor H 2 -3.6 1.E-03
IPI00433138 Discoidin, CUB and LCCL domain-containing protein 2 1 -3.8 6.E-03
IPI00000736 Tetraspanin-15 1 -4.0 1.E-02
IPI00183782 T-lymphocyte surface antigen Ly-9 2 -4.0 2.E-02
IPI00022558 Myelin protein zero-like protein 1 1 -4.0 2.E-02
IPI00216569 Cystatin-F 2 -6.3 6.E-03
IPI00328431 Netrin receptor UNC5B 1 -11.5 4.E-03
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cations (PTM), glycoproteomics has not been applied in
HIV studies. One of the main concerns is whether the
identified change of protein abundance in the patients is
specific to HIV infection. In an attempt to address this
question, we studied in vitro T-cells with latent HIV (i.e.
T cells with HIV DNA integrated into the genome of the
cell but not producing virions) to identify the glycopro-
teins that are preferentially secreted from this type of T
cells. The stage of HIV DNA integration in the viral life
cycle is particularly important because it occurs prior to



































Figure 2 Strategy used for the identification of differentially expresseproductive infection of HIV to a large extent would trig-
ger more intensive host responses than latent infection.
However, the intracellular material from dying cells and
the intense host response due to productive infection
might result in the detection of an abundance of dysreg-
ulated proteins. In contrast, fewer dysregulated proteins
would, presumably, be secreted silently during the latent
stage of T cells. These secreted proteins could constantly
modulate the host immune system due to the longer
survival time of the cells. These cells also remain HIV
replication-competent for potential invasion of the im-
mune system.tion of former N-linked 
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Table 3 N-linked glycoprotein changes in the plasma of HIV+ and HIV- patients and their changed levels in T cells with
HIV latent infection










IPI00759642 Scavenger receptor cysteine-rich type 1 protein M130 3 4.7 2.E-03 - - -
IPI00029756 Tyrosine-protein kinase Mer 2 3.8 2.E-02 - - -
IPI00008494 Intercellular adhesion molecule 1 3 3.0 1.E-02 2 NS NS
IPI00023814 Neogenin 4 2.9 3.E-03 2 3.2 1.E-02
IPI00009477 Intercellular adhesion molecule 2 5 2.9 2.E-06 5 NS NS
IPI00242956 IgGFc-binding protein 12 2.9 1.E-07 - - -
IPI00017841 Noelin 4 2.9 4.E-02 - - -
IPI00004573 Polymeric immunoglobulin receptor 6 2.8 2.E-03 - - -
IPI00011229 Cathepsin D 1 2.8 6.E-03 2 NS NS
IPI00290328 Receptor-type tyrosine-protein phosphatase eta 3 2.7 5.E-03 1 NS NS
IPI00290856 Lymphatic vessel endothelial hyaluronic acid receptor 1 2 2.7 1.E-02 - - -
IPI00437186 Probable G-protein coupled receptor 116 4 2.6 1.E-02 - - -
IPI00166392 Cell adhesion molecule 1 3 2.5 2.E-02 - - -
IPI00015102 CD166 antigen 1 2.5 3.E-03 4 NS NS
IPI00297124 Interleukin-6 receptor subunit beta 1 2.4 3.E-02 2 NS NS
IPI00303071 Adenosine deaminase CECR1 2 2.4 1.E-02 2 3.8 3.E-02
IPI00023673 Galectin-3-binding protein 7 2.3 3.E-07 6 44.5 4.E-03
IPI00218795 L-selectin 3 2.2 1.E-02 2 3.2 3.E-02
IPI00643034 Phospholipid transfer protein 4 2.1 2.E-03 3 5.9 5.E-02
IPI00018136 Vascular cell adhesion protein 1 4 2.0 2.E-02 - - -
IPI00478003 Alpha-2-macroglobulin 6 2.0 3.E-03 - - -
IPI00297263 Protein HEG homolog 1 2 1.9 2.E-02 - - -
IPI00889740 Fibulin 1 2 1.9 4.E-02 - - -
IPI00023014 Von Willebrand factor 9 1.8 3.E-02 - - -
IPI00896380 Ig mu chain C region 5 1.7 5.E-02 - - -
IPI00020986 Lumican 5 1.7 2.E-02 - - -
IPI00414888 ICOS ligand 3 1.7 5.E-02 2 2.6 1.E-02
IPI00022462 Transferrin receptor protein 1 3 1.6 3.E-04 4 NS NS
IPI00973474 Ig gamma-3 chain C region 2 1.6 2.E-02 - - -
IPI00009521 Macrophage receptor MARCO 1 1.5 4.E-02 - - -
IPI00011264 Complement factor H-related protein 1 1 -1.5 4.E-02 - - -
IPI00011252 Complement component C8 alpha chain 1 -1.5 4.E-02 - - -
IPI00879573 Heparin cofactor 2 5 -1.6 2.E-03 - - -
IPI00641737 Haptoglobin 6 -1.6 3.E-02 - - -
IPI00299778 Serum paraoxonase/lactonase 3 1 -1.6 2.E-03 - - -
IPI00028413 Inter-alpha-trypsin inhibitor heavy chain H3 1 -1.7 3.E-02 - - -
IPI00299435 Apolipoprotein F 1 -2.0 2.E-04 - - -
IPI00027507 Complement factor H-related protein 3 3 -2.7 2.E-03 - - -
Plasma (n=20) was analyzed individually by glycoproteomics. The protein fold changes and p-values were calculated as described in the Methods. After 48 hours
of culture, the serum-free media of the HIV latently infected T cell line ACH-2 and its parental cell line A3.01 were compared by glycoproteomics as described in
the Methods. NS - Not Significant.
Yang et al. Clinical Proteomics 2014, 11:9 Page 8 of 11
http://www.clinicalproteomicsjournal.com/content/11/1/9
Yang et al. Clinical Proteomics 2014, 11:9 Page 9 of 11
http://www.clinicalproteomicsjournal.com/content/11/1/9One drawback of using a transformed cell line is that it
does not always function similarly to native infected CD4
+ primary cells that would commonly be used for future
data validation. The identified glycoproteins from T cells
media provide a list of protein candidates that may have a
regulatory role in host-HIV interaction. The association
between the T cell-secreted glycoproteins and HIV infec-
tion in vivo was then analyzed using HIV+ plasma. Based
on the viral load data (Table 1), the patient population
likely represented latent and active viral replication. It is
worth noting that HIV latent infection in T cells persisted
even when viral replication was active. The purpose of
using patient plasma was to determine whether the glyco-
proteins identified from the T cell medium could be de-
tected and whether they were differentially expressed in
HIV infection in general. This study of HIV infected pa-
tient plasma resulted in the identification of six proteins
that were also present in the T cell media. Although the
specificity of the molecules to HIV infection is not conclu-
sive and requires further determination, this first applica-
tion of glycoproteomics to HIV latently infected T cells
and HIV+ plasma elucidated significantly higher levels of
glycoproteins that could aid future studies that are de-
signed to understand host-HIV interaction in vivo.
HIV latent infection could affect the protein T cell pro-
tein secretion, and the secreted proteins could be potent
immuno-modulators. We hypothesized that the secretion
or leaking of protein from these HIV infected T cells might
contribute to the dysregulation of glycoproteins in the
plasma of HIV-infected patients. To evaluate this possibil-
ity, ACH-2 and its parental A3.01 cell line were studied be-
cause of their ability to mimic the latent infection of HIV,
although these cell lines behave differently from canonical
peripheral blood mononuclear cell (PBMC) in many as-
pects. Nevertheless, the T cell lines were homogeneous and
they provided direct evidence supporting the proposed hy-
pothesis. Our glycoproteomic study of the media from
these T cells identified 59 glycoproteins with at least a 3-
fold change and p-value < 0.05. These glycoproteins could
be of interest because their increased levels might have a
regulatory effect in the host response. Next, to determine
whether any of the changes in protein levels in the T cell
media were also detected in the plasma from HIV+ pa-
tients, we employed a strategy that used pooled samples
for the initial screen and individual samples for the down-
stream high throughput verification. The use of this strat-
egy is thought to solve some of the issues associated with
ELISA testing (i.e. relatively poor sensitivity of detection
and lack of cost effectiveness in evaluating a large number
of proteins). Although the strategy limited the sample size
here, it is noteworthy that a strategy could be developed
that begins with the analysis of pooled samples and is then
followed by verification using a predetermined number of
randomly selected samples from the pools.The analysis of pooled samples identified 103 glyco-
proteins between the HIV+ and HIV-group with a cut-
off ratio of 1.3-fold. The low cut-off ratio retained as
many proteins as possible in the list for subsequent MS
verification. The 20 samples were then analyzed indi-
vidually by three technical replicates and the results in-
dicated that 38 proteins were differentially expressed
between groups. The analysis of individual samples per-
mitted the statistical evaluation (p-value ≤ 0.05) of each
protein in the list. A fold change in the same trend ob-
served in the analysis of the pooled and individual sam-
ples provided a means to verify these proteins. These 38
proteins accounting for 36.9% of the total 103 proteins
suggested that HIV infection has a moderate effect on
glycoproteins, although it was not clear whether the ef-
fect was on protein expression or the glycosylation level
of the changed glycoproteins.
Among these 38 proteins, four proteins – galectin-3-
binding protein, L-selectin, neogenin, and phospholipid
transfer protein – were determined to have an increase
of at least 3-fold in the medium of virus latently infected
T cells and a 2-fold increase in HIV+ plasma. Galectin-3-
binding protein was the most significantly up-regulated
protein in the medium of ACH-2 cells. Although
galectin-3-binding protein has been reported to be ele-
vated in HIV infection and cancer [45], the cause of its
elevation in either disease is unclear in vivo. The up-
regulation of galectin-3-binding protein in the medium
of ACH-2 cells suggested that T cells latently infected
with HIV could contribute to the elevation of galectin-3-
binding protein that was observed in the plasma of HIV+
patients. Interestingly, an increase of L-selectin in HIV
infection has been reported to function in the homing of
T lymphocytes to the peripheral lymph nodes for apop-
tosis [46-48]. This mechanism possibly explains the
massive loss of these cells without obvious intracellular
HIV replication [46-48]. Shedding of L-selectin is re-
ported to be induced through the engagement of HIV to
both CD4 and CXCR4 [48]. Our results indicate that
HIV latency could result in the secretion of L-selectin as
well. It is more likely that the dysregulation of proteins
in the plasma is a consequence of an orchestrated series
of host responses.
Four proteins – neogenin, adenosine deaminase CECR1,
ICOS ligand and phospholipid transfer protein – may also
participate in host-HIV interaction. Neogenin, which be-
longs to the immunoglobulin superfamily, is a multifunc-
tional transmembrane receptor. In neogenin−/− animals,
significant attenuation of induced inflammation has been
observed, and, interestingly, direct injection of anti-
neogenin antibody in animals also significantly reduces in-
flammation [49,50]. These studies suggest that neogenin
may play an important role in chronic inflammation in-
duced by HIV infection. Elevated levels of neogenin were
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regulation of its level may have a therapeutic value in HIV+
patients. Adenosine deaminase CECR1 functions to de-
grade extracellular adenosine, and it has been reported to
increase the proliferation rate of CD4 T cells and macro-
phages independent of its enzyme activity [51]. The in-
creased proliferation of these cell populations with a
portion of them harboring HIV latency may result in the
expansion of the HIV reservoir. ICOS ligand and the
ICOS pathway function to trigger effector T cell responses
and generate follicular helper T cells [52]. HIV infection
severely affects the effector T cell population [53]. Pro-
longed activation of effector T cells by ICOS ligand could
lead to progressive exhaustion. In addition, a recent study
reported that the main CD4 T cell compartment for HIV
is follicular helper T cells [54]. Thus, excessive ICOS lig-
and may stimulate the generation of such cells whose in-
crease in number supports future HIV infection and
replication. Phospholipid transfer protein functions in
lipoprotein metabolism and lipid transport in the vascular
compartment. Its levels could be changed in different hu-
man diseases and conditions [55]. Our finding of elevated
phospholipid transfer protein levels could be a result of
overall immune activation or inflammatory reaction trig-
gered by HIV chronic infection. Aside from the four pro-
teins mentioned above, other proteins among those listed
in Tables 2 & 3 may be of interest in regard to their poten-
tially important roles in HIV infection. A careful selection
of the proteins merits future investigation.Conclusion
To our knowledge, this study is the first application of
glycoproteomics in HIV latently infected T cell medium
and HIV+ plasma. We identified several glycoproteins
with differential expression in the medium of an HIV in-
fected T cell model and HIV+ plasma. The correlation of
the proteins observed in the medium of HIV+ T cells
and plasma was not clear in the study. To specifically as-
sociate the changed glycoproteins with HIV infection,
the analysis of clearly defined patient cohorts merits fu-
ture glycoproteomic investigation.Additional files
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